April 4 (Reuters) - Britain's competition watchdog said

Theramex's purchase of European rights to two of Viatris' ( VTRS )

women's healthcare products ranges could lead to higher

prices and lesser options for hormone replacement therapy

treatments.

Drugmaker Viatris agreed to sell its rights to Duphaston and

Femoston product ranges to London-based Theramex in October.

(Reporting by Prerna Bedi in Bengaluru; Editing by Shinjini

Ganguli)